sign in sign up
<<
Home , Capmatinib, Incyte

INCYTE PORTFOLIO

Targeted Therapy Clinical Proof of Concept Pivotal Approved Immuno-Oncology Clinical Proof of Concept Pivotal Approved

® 1 8 Jakafi () Myelofibrosis2, polycythemia vera2, acute and chronic GVHD2 retifanlimab Squamous cell anal carcinoma, NSCLC JAK1/JAK2 PD-1

® 8 Pemazyre () Cholangiocarcinoma3 retifanlimab MSI-H endometrial cancer, Merkel cell carcinoma FGFR1/2/3 PD-1

® 4 8 Monjuvi (-cxix) retifanlimab Solid tumors ® 4 2,5,6 PD-1 Minjuvi (tafasitamab) Diffuse large B-cell CD19 INCB86550 Solid tumors ® 7 PD-L1 Iclusig () Chronic myeloid leukemia5, Ph+ acute lymphoblastic leukemia5 BCR-ABL 9 MCLA-145 Solid tumors PD-L1xCD137 ruxolitinib + parsaclisib Myelofibrosis JAK1/JAK2, PI3Kδ INCB81776 Multiple tumor types AXL/MER parsaclisib Follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma PI3Kδ epacadostat Solid tumors 4 IDO1 tafasitamab Follicular lymphoma, marginal zone lymphoma CD19 10 INCB01158 Multiple tumor types 4 ARG tafasitamab + parsaclisib Chronic lymphocytic CD19, PI3Kδ INCB106385 Solid tumors A2A/A2B itacitinib Myelofibrosis JAK1 INCA00186 Solid tumors CD73 pemigatinib Solid tumors, MLN with FGFR1 rearrangement FGFR1/2/3 11 INCAGN1876 Solid tumors GITR INCB57643 Myelofibrosis BET 11 INCAGN1949 Solid tumors OX40 INCB00928 Anemia due to hematological disorders including MF ALK2 11 INCAGN2390 Solid tumors TIM-3

11 INCAGN2385 Solid tumors Inflammation/ Autoimmunity LAG-3

Dermatology

Opzelura™ (ruxolitinib) cream Atopic dermatitis2 Partnered JAK1/JAK2

® 12 ruxolitinib cream Vitiligo Olumiant () Rheumatoid arthritis13, atopic dermatitis5 JAK1/JAK2 JAK1/JAK2

® 14 INCB54707 Hidradenitis suppurativa, vitiligo Tabrecta (capmatinib) NSCLC with METex1415 JAK1 MET

12 baricitinib Systemic lupus erythematosus, alopecia areata, COVID-1916 Other JAK1/JAK2

14 INCB00928 Fibrodysplasia ossificans progressiva capmatinib Liver cancer ALK2 MET

parsaclisib Autoimmune hemolytic anemia PI3Kδ

Updated as of September 22, 2021 Please refer to local prescribing information for more information, including full safety information, on Incyte’s marketed medicines, or on medicines marketed by Incyte’s collaboration partners. 1. Jakafi marketed by Incyte in the U.S.; ruxolitinib licensed to outside the U.S. 2. Approved in the U.S. 3. Approved in multiple territories, including the U.S., Canada, Europe, and Japan 4. Development in collaboration with MorphoSys and co-commercialization in the U.S. with MorphoSys; exclusive commercialization rights held by Incyte outside the U.S. 5. Approved in Europe 6. Approved in Canada 7. European rights to Iclusig licensed from Takeda 8. In collaboration with MacroGenics 9. Exclusive development and commercialization rights held by Incyte outside the U.S., by Merus in the U.S. 10. Licensed from Calithera 11. Discovery collaboration with Agenus 12. Worldwide rights to baricitinib licensed to Lilly 13. Approved in multiple territories globally 14. Worldwide rights to capmatinib licensed to Novartis 15. Approved in the U.S. and Japan 16. Authorized in the U.S. for use under an EUA, for treatment of COVID-19 in certain hospitalized patients. EUA, Emergency Use Authorization; FGFR, fibroblast receptor; GVHD, graft-versus-host disease; MF, myelofibrosis; MLN, myeloid/lymphoid neoplasms; MSI-H, microsatellite instability-high; NSCLC, non-small cell lung cancer; Ph+, -positive.